Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GoodRx HoldingsGDRX +3.68%70 EV-to-EBIT is 18.72 as of Aug. 11, 2026, which is 15% below its 10-year median of 22.11. GuruFocus rates GDRX with a GF Score™ of 70/100 and a GF Value™ of $5.29 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 473 Healthcare Providers & Services companies, GoodRx Holdings ranks worse than 58.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
GoodRx Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $1,245.2 Mil.
GoodRx Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $82.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GoodRx Holdings EV-to-EBIT Related Terms
GoodRx Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for GoodRx Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, GoodRx Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GoodRx Holdings EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, GoodRx Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where GoodRx Holdings's EV-to-EBIT falls into.
GoodRx Holdings's current Enterprise Value is $1,539.2 Mil.
GoodRx Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $82.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GoodRx Holdings (GDRX) has a EV-to-EBIT of 18.72 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GoodRx Holdings and its competitors. This is 15% below median its historical median of 22.11. According to the industry distribution chart, GoodRx Holdings ranks #278 out of 473 companies in the Healthcare Providers & Services industry, placing it in the top 58.8%.
Is GoodRx Holdings' EV-to-EBIT too high?
GoodRx Holdings' current EV-to-EBIT of 18.72 is 15% below median its 10-year median of 22.11. The Healthcare Providers & Services industry median EV-to-EBIT is 15.73. GoodRx Holdings' value of 18.72 is 19% above this industry median. Based on the distribution chart, GoodRx Holdings ranks #278 out of 473 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, GoodRx Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GoodRx Holdings' EV-to-EBIT compare to SDGR and TALK?
According to the Healthcare Providers & Services industry distribution chart, GoodRx Holdings ranks #278 out of 473 companies for EV-to-EBIT. This places GoodRx Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.73. GoodRx Holdings' value of 18.72 is 19% above this benchmark. While the company's 10-year median is 22.11 vs. the industry median of 15.73, GoodRx Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.73, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GoodRx Holdings's current EV-to-EBIT of 18.72 is 19% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GoodRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GoodRx Holdings's current EV-to-EBIT is 18.72, which is 15% below median its own 10-year median of 22.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GoodRx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GoodRx Holdings (GDRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.29, compared to a current price of $3.80 — trading 28.2% below its estimated fair value. The current EV-to-EBIT is 18.72, which is 15% below median its 10-year median of 22.11 and 19% above the Healthcare Providers & Services industry median of 15.73. GoodRx Holdings' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For GoodRx Holdings (GDRX), the current EV-to-EBIT is 18.72 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GoodRx Holdings (GDRX) Overvalued in 2026?
Based on GuruFocus' analysis, GoodRx Holdings stock appears to be undervalued.
The current stock price of $3.80 is trading 28.2% below its estimated GF Value™ of $5.29.
GuruFocus considers GoodRx Holdings to be Modestly Undervalued.
Key valuation signals for GDRX:
EV-to-EBIT: 18.72 (15% below median its 10-year median of 22.11)
GF Value™: $5.29 vs. price of $3.80 (28.2% below fair value)
Industry Position: 19% above the Healthcare Providers & Services median (#278 of 473)
No single metric tells the full story. See the GDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
70GF Score
Get the complete analysis for GDRX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDRX has been successfully added to your 
